Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
Delayed Quote. Delayed Nyse - 10/15 04:10:00 pm
112.16 USD   +0.53%
10/11INSIDER SELL : Edwards Lifesciences
MT
10/04Edwards Lifesciences on Pace for Largest Percent Decrease Since October 2020 -- Data Talk
DJ
10/04INSIDER SELL : Edwards Lifesciences
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Tranche Update on Edwards Lifesciences Corporation (NYSE:EW)'s Equity Buyback Plan announced on May 5, 2021.

07/30/2021 | 04:07pm EDT

From May 4, 2021 to June 30, 2021, the company has repurchased 0 shares, representing 0% for $0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for $0 million under the buyback announced on May 5, 2021.


ę S&P Capital IQ 2021
All news about EDWARDS LIFESCIENCES CORPORATION
10/11INSIDER SELL : Edwards Lifesciences
MT
10/04Edwards Lifesciences on Pace for Largest Percent Decrease Since October 2020 -- Data Ta..
DJ
10/04INSIDER SELL : Edwards Lifesciences
MT
09/16INSIDER SELL : Edwards Lifesciences
MT
09/13INSIDER SELL : Edwards Lifesciences
MT
09/09INSIDER SELL : Edwards Lifesciences
MT
09/05HOUSTON WE HAVE : Edwards Lifesciences to Fund Houston We Have's Clinical Trial of ECHOiQ'..
MT
08/03EDWARDS LIFESCIENCES : Goldman Sachs Adjusts Edwards Lifesciences' Price Target to $105 fr..
MT
08/02EDWARDS LIFESCIENCES : Raymond James Adjusts Edwards Lifesciences' Price Target to $122 fr..
MT
08/02EDWARDS LIFESCIENCES : initiates $100 million social impact investment fund to advance rac..
PU
More news
Analyst Recommendations on EDWARDS LIFESCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 5 335 M - -
Net income 2021 1 422 M - -
Net cash 2021 1 462 M - -
P/E ratio 2021 48,8x
Yield 2021 -
Capitalization 69 912 M 69 912 M -
EV / Sales 2021 12,8x
EV / Sales 2022 11,4x
Nbr of Employees 14 900
Free-Float 96,6%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | EW | US28176E1082 | MarketScreener
Technical analysis trends EDWARDS LIFESCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 112,16 $
Average target price 117,65 $
Spread / Average Target 4,90%
EPS Revisions
Managers and Directors
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
Nicholas J. Valeriani Independent Director
Kieran Thomas Gallahue Independent Director
Sector and Competitors